A Study to Compare Two Bioanalytical Assays for Tebipenem

NCT05856747 | Completed Phase 1 FDA Drug

• 1 other identifier: SPR994-109
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of the study is to compare the concentrations of tebipenem (TBP), the active moiety of tebipenem pivoxil hydrobromide (TBP-PI-HBr), as determined by two bioanalytical assays, a whole blood assay and a plasma assay, following a single oral dose of TBP-PI-HBr 600 milligram (mg) tablets in healthy adult participants.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (3)

• Percentage of Tebipenem (TBP) Samples With Converted (From Whole Blood Measurements) and Measured Plasma Concentrations That Have a Difference not Exceeding ±20% of the Mean of the Concentrations

  Pre dose and at multiple time points post dose on Day 1

• Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUC0-∞) of TBP

  Pre dose and at multiple time points post dose on Day 1

• Maximum Plasma Concentration (Cmax) of TBP

  Pre dose and at multiple time points post dose on Day 1

Secondary Outcomes (1)

• Number of Participants With Adverse Events (AEs)

  From first dose of study drug up to Day 6

Study Arms (1)

TBP-PI-HBr 600 mg

EXPERIMENTAL

Healthy participants meeting eligibility criteria will receive a single oral dose of TBP-PI-HBr 600 mg tablets (2 x 300 mg) on Day 1 under fasted conditions.

Drug: TBP-PI-HBr

Interventions

TBP-PI-HBr DRUG

TBP-PI-HBr tablets.

Also known as: SPR994

TBP-PI-HBr 600 mg

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Body mass index (BMI) ≥18.0 and ≤32.0 kilograms per meter square (kg/m\^2) at Screening visit.
• Medically healthy with no clinically significant medical history, abnormalities in physical examination, laboratory variables, vital signs or electrocardiogram (ECG) at the time of Screening visit and Check-in (Day-1), as deemed by the investigator or designee.
• Have suitable venous access for repeated blood sampling.

You may not qualify if:

• Any clinically significant medical history or observations at the time of Screening visit or Check-in (Day -1) not specifically excluded in other criteria that, in the opinion of the investigator or designee, may confound the results of the study, compromise the safety of the participant or otherwise render the participant unsuitable for participation.
• Use/receipt of any prescription or non-prescription medication, herbal products, vitamins or vaccines within 14 days (or 5 half-lives whichever is longer) prior to Check-in (Day -1).
• Positive coronavirus disease (COVID-19) screening test using polymerase chain reaction (PCR) or antigen assay at Screening visit or Check-in (Day -1).
• Donation or significant blood loss of more than 500 milliliter (mL) of blood within 56 days prior to enrollment, or receipt of a blood transfusion within 1 year prior to enrollment; plasma donation within 7 days prior to dosing.
• ECG with corrected QT interval by Fridericia (QTcF) interval duration equal or greater than 450 milliseconds (msec) for males and 470 msec for females obtained after at least 5 minutes in a supine or semi-recumbent position at quiet rest at Screening visit or Check-in (Day -1).

Sponsors & Collaborators

• Spero Therapeutics: lead

Study Sites (1)

BioPharma Services

Creve Coeur, Missouri, 63141, United States

Location

MeSH Terms

Interventions

tebipenem

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 3, 2023
• First Posted: May 12, 2023
• Study Start: May 4, 2023
• Primary Completion: June 1, 2023
• Study Completion: June 1, 2023
• Last Updated: March 27, 2024

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)